Zenith Epigenetics Appoints Julie Cherrington as President and CEO

28-Jul-2014 - Canada

Zenith Epigenetics Corp. announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer of Zenith Epigenetics Corp. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization.  Her accomplished employment record includes past notable positions such as CEO of Pathway Therapeutics Inc., President of Phenomix Corporation, Vice President, Preclinical Research and Exploratory Development SUGEN/Pharmacia/Pfizer, and Director, Virology at Gilead Sciences. Notably, Julie was a key contributor to the successful development of multiple FDA approved products including anti-virals and anti-cancer agent.

Donald J. McCaffrey , founding CEO, will assume the title of Chairman and Dr. Peter Johann will act as Lead Director.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances